Cumberland Pharmaceuticals CPIX Study Drug — Non-current inventories
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cumberland Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryNoncurrent.
The official record: Cumberland Pharmaceuticals’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cumberland Pharmaceuticals's study drug — non-current inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cumberland Pharmaceuticals's study drug — non-current inventories?
- Cumberland Pharmaceuticals (CPIX) reported study drug — non-current inventories of $40.88K in Q4 2025.
- What does study drug — non-current inventories mean?
- This metric represents the carrying value of inventory associated with clinical-stage or development-phase pharmaceutical products that are not expected to be sold or utilized within the next twelve months. It reflects the long-term investment in drug supply held for future clinical trials or anticipated commercialization beyond the current operating cycle. Monitoring this balance provides insight into the company's pipeline development progress and the potential for future product launches.